Cargando…

Correction: Stem Cell Selection In Vivo Using Foamy Vectors Cures Canine Pyruvate Kinase Deficiency

Detalles Bibliográficos
Autores principales:	Trobridge, Grant D., Beard, Brian C., Wu, Robert A., Ironside, Christina, Malik, Punam, Kiem, Hans-Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813779/ http://dx.doi.org/10.1371/annotation/90f278b2-f474-42ec-8645-435f7006018c

Ejemplares similares

Stem Cell Selection In Vivo Using Foamy Vectors Cures Canine Pyruvate Kinase Deficiency
por: Trobridge, Grant D., et al.
Publicado: (2012)

Large Animal Models for Foamy Virus Vector Gene Therapy
por: Trobridge, Grant D., et al.
Publicado: (2012)

Foamy Virus Vectors for HIV Gene Therapy
por: Olszko, Miles E., et al.
Publicado: (2013)

In-Vivo Gene Therapy with Foamy Virus Vectors
por: Rajawat, Yogendra Singh, et al.
Publicado: (2019)

Foamy Combinatorial Anti-HIV Vectors with MGMTP140K Potently Inhibit HIV-1 and SHIV Replication and Mediate Selection In Vivo
por: Kiem, Hans-Peter, et al.
Publicado: (2009)

Evidence for the in vivo safety of insulated foamy viral vectors
por: Browning, Diana L., et al.
Publicado: (2016)

Prospects for Foamy Viral Vector Anti-HIV Gene Therapy
por: Nalla, Arun K., et al.
Publicado: (2016)

A comparison of foamy and lentiviral vector genotoxicity in SCID-repopulating cells shows foamy vectors are less prone to clonal dominance
por: Everson, Elizabeth M, et al.
Publicado: (2016)

Retargeted Foamy Virus Vectors Integrate Less Frequently Near Proto-oncogenes
por: Hocum, Jonah D., et al.
Publicado: (2016)

Production and purification of high-titer foamy virus vector for the treatment of leukocyte adhesion deficiency
por: Nasimuzzaman, Md, et al.
Publicado: (2016)

Treatment of canine leukocyte adhesion deficiency by foamy virus vectors expressing CD18 from a PGK promoter
por: Bauer, Thomas R, et al.
Publicado: (2011)

In vivo Selection of Autologous MGMT Gene-Modified Cells Following Reduced Intensity Conditioning with BCNU and Temozolomide in the Dog Model
por: Gori, Jennifer L., et al.
Publicado: (2012)

Development of the pyruvate kinase deficiency diary and pyruvate kinase deficiency impact assessment: Disease‐specific assessments
por: Salek, Sam, et al.
Publicado: (2020)

Preclinical studies of efficacy thresholds and tolerability of a clinically ready lentiviral vector for pyruvate kinase deficiency treatment
por: Navarro, Susana, et al.
Publicado: (2021)

Molecular heterogeneity of pyruvate kinase deficiency
por: Bianchi, Paola, et al.
Publicado: (2020)

Pyruvate Kinase Deficiency Causing Priapism
por: Shankar, Vinay Hanyalu, et al.
Publicado: (2023)

Protection of Stem Cell-Derived Lymphocytes in a Primate AIDS Gene Therapy Model after In Vivo Selection
por: Trobridge, Grant D., et al.
Publicado: (2009)

VISA - Vector Integration Site Analysis server: a web-based server to rapidly identify retroviral integration sites from next-generation sequencing
por: Hocum, Jonah D., et al.
Publicado: (2015)

Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector
por: Becker, Pamela S., et al.
Publicado: (2010)

Pigtailed macaques as a model to study long-term safety of lentivirus vector-mediated gene therapy for hemoglobinopathies
por: Kiem, Hans-Peter, et al.
Publicado: (2014)

Comorbidities and complications in adults with pyruvate kinase deficiency
por: Boscoe, Audra N., et al.
Publicado: (2021)

Psychometric validation of the Pyruvate Kinase Deficiency Diary and Pyruvate Kinase Deficiency Impact Assessment in adults in the phase 3 ACTIVATE trial
por: Andrae, David A., et al.
Publicado: (2023)

Foamy Virus Biology and Its Application for Vector Development
por: Lindemann, Dirk, et al.
Publicado: (2011)

Efficient liver gene transfer with foamy virus vectors
por: Zacharoulis, Dimitris, et al.
Publicado: (2013)

Delivery of large transgene cassettes by foamy virus vector
por: Sweeney, Nathan Paul, et al.
Publicado: (2017)

Erythrocyte pyruvate kinase deficiency: 2015 status report
por: Grace, Rachael F., et al.
Publicado: (2015)

Novel mutations associated with pyruvate kinase deficiency in Brazil
por: Svidnicki, Maria Carolina Costa Melo, et al.
Publicado: (2018)

The variable manifestations of disease in pyruvate kinase deficiency and their management
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Pyruvate Kinase Deficiency: Current Challenges and Future Prospects
por: Fattizzo, Bruno, et al.
Publicado: (2022)

Foamy Virus Vectors Transduce Visceral Organs and Hippocampal Structures following In Vivo Delivery to Neonatal Mice
por: Counsell, John R., et al.
Publicado: (2018)

Foamy Virus Integrase in Development of Viral Vector for Gene Therapy
por: Kim, Jinsun, et al.
Publicado: (2020)

Pyruvate Kinase, Inflammation and Periodontal Disease
por: Grant, Melissa M.
Publicado: (2021)

Efficient production of inhibitor-free foamy virus glycoprotein-containing retroviral vectors by proteoglycan-deficient packaging cells
por: Munz, Clara Marie, et al.
Publicado: (2022)

Insulators to Improve the Safety of Retroviral Vectors for HIV Gene Therapy
por: Browning, Diana L., et al.
Publicado: (2016)

Identifying Cancer Driver Genes Using Replication-Incompetent Retroviral Vectors
por: Bii, Victor M., et al.
Publicado: (2016)

Prevalence of pyruvate kinase deficiency: A systematic literature review
por: Secrest, Matthew H., et al.
Publicado: (2020)

Red Blood Cell Metabolism in Pyruvate Kinase Deficient Patients
por: Roy, Micaela K., et al.
Publicado: (2021)

Pyruvate kinase deficiency in a newborn with extramedullary hematopoiesis in the skin
por: Voit, Richard A., et al.
Publicado: (2020)

Treating pyruvate kinase deficiency with Mitapivat: a short communication
por: Larik, Muhammad Omar, et al.
Publicado: (2023)

Feline Foamy Virus-Based Vectors: Advantages of an Authentic Animal Model
por: Liu, Weibin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_omfngpc3j1p7jljnoordk6qa0k